Optimind Pharma Corp.
OMND
CNSX
| 11/30/2025 | 08/31/2025 | 05/31/2025 | 02/28/2025 | 11/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 24.40K | 19.70K | 25.40K | 24.20K | 19.30K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 24.40K | 19.70K | 25.40K | 24.20K | 19.30K |
| Cost of Revenue | 13.40K | 8.60K | 7.50K | 9.10K | 7.90K |
| Gross Profit | 10.90K | 11.10K | 17.90K | 15.10K | 11.40K |
| SG&A Expenses | 24.90K | 15.80K | 16.90K | 30.40K | 16.40K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 38.30K | 24.40K | 24.40K | 39.50K | 24.20K |
| Operating Income | -13.90K | -4.70K | 1.00K | -15.30K | -4.90K |
| Income Before Tax | -20.50K | -7.90K | -200.00 | -18.70K | -6.60K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -20.50K | -7.90K | -200.00 | -18.70K | -6.60K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -20.50K | -7.90K | -200.00 | -18.70K | -6.60K |
| EBIT | -13.90K | -4.70K | 1.00K | -15.30K | -4.90K |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 103.15M | 103.15M | 104.70M | 109.90M | 109.79M |
| Average Diluted Shares Outstanding | 103.15M | 103.15M | 104.70M | 109.90M | 109.79M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |